Schlagen Frauenherzen anders?

Einleitung

Die Manifestationen der koronaren Herzerkrankung (KHK) unterscheiden sich sehr deutlich zwischen Frauen und Männern, ebenso wie das Ergebnis therapeutischer Interventionen [1]. Es ist wichtig, dass die behandelnden Ärzte diese Unterschiede, die sicher in Zukunft an Bedeutung gewinnen werden, kennen. In dieser Übersichtsarbeit sind prägnante Geschlechterunterschiede in Epidemiologie und Klinik der KHK, in der zugrunde liegenden molekularen Pathophysiologie, Risikofaktoren und Diagnostik sowie in der medikamentösen Therapie zusammengefasst.

Literatur

• 1 Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease.  Nat Rev Drug Discov. 2006;  5 425-439
• 2 Lowel H, Meisinger C, Heier M, Hormann A, Kuch B, Gostomzyk J, Koenig W. Sex specific trends of sudden cardiac death and acute myocardial infarction: results of the population-based KORA/MONICA-Augsburg register 1985 to 1998.  Dtsch Med Wochenschr. 2002;  127 2311-2316
• 3 Regitz-Zagrosek V, Lehmkuhl E, Lehmkuhl H B, Hetzer R. Gender aspects in heart failure. Pathophysiology and medical therapy.  Arch Mal Coeur Vaiss. 2004;  97 899-908
• 4 Mieres J H, Shaw L J, Arai A. et al . Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association.  Circulation. 2005;  111 682-696
• 5 Redberg R F, Cannon R O 3rd, Bairey M erz, Lerman A, Reis S E, Sheps D S. Women’s Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2 - 4, 2002: Section 2: stable ischemia: pathophysiology and gender differences.  Circulation. 2004;  109 e47-49
• 6 Vaccarino V, Parsons L, Every N R, Barron H V, Krumholz H M. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants.  N Engl J Med. 1999;  341 217-225
• 7 Antoniucci D, Valenti R, Moschi G. et al . Sex-based differences in clinical and angiographic outcomes after primary angioplasty or stenting for acute myocardial infarction.  Am J Cardiol. 2001;  87 289-293
• 8 Vaccarino V, Abramson J L, Veledar E, Weintraub W S. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women.  Circulation. 2002;  105 1176-1181
• 9 Regitz-Zagrosek V, Lehmkuhl E, Hocher B. et al . Gender as a risk factor in young, not in old, women undergoing coronary artery bypass grafting.  J Am Coll Cardiol.. 2004;  44 2413-2414
• 10 Makkar R R, Fromm B S, Steinman R T, Meissner M D, Lehmann M H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.  JAMA. 1993;  270 2590-2597
• 11 Rodriguez I, Kilborn M J, Liu X K, Pezzullo J C, Woosley R L. Drug-induced QT prolongation in women during the menstrual cycle.  JAMA. 2001;  285 1322-1326
• 12 Theres H, Maier B, Matteucci G othe. et al . Influence of gender on treatment and short-term mortality of patients with acute myocardial infarction in Berlin.  Z Kardiol. 2004;  93 954-963
• 13 Yusuf S, Ounpuu S, Dans T, INTERHEART S tudy. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.  Lancet. 2004;  364 937-952
• 14 Shaw L J, Merz N B, Pepine C J. et al . for the WISE Investigation. Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies.  J Am Coll Cardiol. 2006;  46 4S-20S
• 15 Stramba-Badiale M, Fox K M, Priori S G. et al . Cardiovascular diseases in women: a statement from the policy conference of the European society of cardiology.  Eur Heart J. 2006;  27 994-1005
• 16 Tanis B C, van den Bosch M AAJ, Kemmeren J M. et al . Oral contraceptives and the risk of myocardial infarction.  N Engl J Med. 2001;  345 1787-1793
• 17 Diverse P opulations. Smoking, body weight, CHD mortality in diverse populations.  Prev Medicine. 2004;  38 834-840
• 18 McLarty A, Mann N, Lawson W, Forster A. Womens heart health series: a mini-symposium.  Med Sci Monit. 2003;  9 103-110
• 19 Fröhlicher E S, Miller N H, Christopherson D J. et al . High rates of sustained smoking cessation in women hospitalized with cardiovascular disease.  Circulation. 2004;  109 587-593
• 20 Manolio T A, Pearson T A, Wenger N K, Barrett-Connor E, Payne G H, Harlan W R. Cholesterop and heart disease in older persons and women. Review of an NHLBI workshop.  Ann Epidemiol. 1992;  2 161-176
• 21 Hokanson J E, Austin M A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein level: a meta-analysis of population based prospective Studies.  J Cardiovasc Risk. 1996;  3 213-219
• 22 Stessen J A, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatori blood pressure and menopause in a prospective population study.  J Hum Hypertens. 1997;  11 507-514
• 23 Mason P J, Manson J E, Sesso H D. et al . Blood pressure and risk of secondary cardiovascular events in women.  Circulation. 2004;  109 1623-1629
• 24 Steingart R M, Packer M, Hamm P. et al . Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators.  N Engl J Med. 1991;  325 226-230
• 25 Conroy R M, Pyörälä K, Fitzgerald A P. et al . on behalf of the SCORE project group. Estimation of ten-year risk of fatatl cardiovascular disease in Europe: the SCORE project.  Eur Heart J. 2003;  24 987-1003
• 26 Huxley R, Barzi F, Woodward M. Excess of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.  BMJ. 2006;  332 73-78
• 27 Weiss R, Dziura J, Burgert T S. et al . Obesity and the metabolic syndrome in Children and Adolescents.  N Engl J Med. 2004;  350 2362-2374
• 28 Regitz-Zagrozek V, Lehmkuhl E, Weickert M O. Gender differences in the metabolic syndrome and their role for cardiovascualr disease.  Clin Res Cardiol. 2006;  95 136-147
• 29 Wessel T R, Arant C B, Olson M B. et al . Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women.  JAMA. 2004;  292 1179-1187
• 30 Yusuf S, Hawken S, Ounpuu S. et al . ; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27. 000 participants from 52 countries: a case-control study.  Lancet. 2005;  366 1640-1649
• 31 Li T Y, Rana J S, Manson J E. et al . Obesity as compared with physical activity in predicting risk of coronary artery disease.  Circulation. 2006;  113 499-506
• 32 Ross R. Atherosclerosis an inflammatory disease.  N Engl J Med. 1999;  340 115-126
• 33 Brezinka V, Kittel F. Psychosocial factors of coronary heart disease in women: a review.  Social Science and Medicine. 1996;  42 1351-1362
• 34 Bjerkest O, Nordahl H N, Mykletun A, Holmen J, Dahl A A. Anxiety and depression following myocardial infarction: gender differences in a 5-year prospective study.  J Psychosom Res. 2005;  58 153-161
• 35 Abogast A, Sechtem U. Diagnose der koronaren Herzkrankheit bei Frauen.  Dtsch Med Wochenschr. 2003;  128 97-102
• 36 Gibbons R J, Balady G J, Bricker J T. et al . ACC/AHA 2002 guidelines update for exercise testing: summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines.  Circulation. 2002;  106 1883-1892
• 37 Mora S, Redberg R F, Cui Y. et al . Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study.  JAMA. 2003;  290 1600-1607
• 38 Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women.  Am J Cardiol. 1999;  83 660-666
• 39 Okin P M. Elektrocardiography in women. Taking the initiative.  Circulation. 2006;  113 464-466
• 40 Shaw L J, Vasey C, Sawada S, Rimmerman C, Marwick T H. Impact of gender on risk stratifitcation by exercise and dobutamine stress echocardiography: long-term mortality in 4234 women and 6898 men.  Eur Heart J. 2005;  26 447-456
• 41 Mieres J H, Shaw L J, Hendel R C. et al . ; Writing Group on Perfusion Imaging in Women. American Society of Nuclear Cardiology consensus statement: Task Force on Women and Coronary Artery Disease-the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women.  J Nucl Cardiol. 2003;  10 95-101
• 42 Buchthal S D, den H ollander, Merz C NB. et al . Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms.  N Engl J Med. 2000;  342 829-835
• 43 Liao Y, Cooper R S, Mensah G A, McGee D L. Left ventricular hypertrophy has a greater impact on survival in women than in men.  Circulation. 1995;  92 805-810
• 44 Cleland J G, Swedberg K, Follath F. et al . The EuroHeart Failure survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.  Eur Heart J. 2003;  24 442-463
• 45 Mendelsohn M E, Karas R H. Molecular and cellular basis of cardiovascular gender differences.  Science. 2005;  308 1583-1587
• 46 Nordmeyer J, Eder S, Mahmoodzadeh S. et al . Upregulation of myocardial estrogen receptors in human aortic stenosis.  Circulation. 2004;  110 3270-3275
• 47 Mahmoodzadeh S, Eder S, Nordmeyer J. et al . Estrogen receptor alpha up-regulation and redistribution in human heart failure.  Faseb J. 2006;  20 926-934
• 48 Edwards D P. Regulation of signal transduction pathways by estrogen and progesterone.  Annu Rev Physiol. 2005;  67 335-376
• 49 Dubey R K, Tofovic S P, Jackson E K. Cardiovascular pharmacology of estradiol metabolites.  J Pharmacol Exp Ther. 2004;  308 403-409
• 50 Sudhir K, Komesaroff P A. Clinical review 110: Cardiovascular actions of estrogens in men.  J Clin Endocrinol Metab. 1999;  84 3411-3415
• 51 Herrington D M, Howard T D. ER-alpha variants and the cardiovascular effects of hormone replacement therapy.  Pharmacogenomics. 2003;  4 269-277
• 52 Berry C, Kelly J, Cobbe S M, Eteiba H. Comparison of femoral bleeding complication after coronary angiography versus percutaneous coronary intervention.  Am J Cardiol. 2004;  94 361-363
• 53 Rubanyi G M, Kauser K, Johns A. Role of estrogen receptors in the vascular system.  Vascul Pharmacol. 2002;  38 81-88
• 54 Rathore S S, Wang Y, Krumholz H M. Sex-based differences in the effect of digoxin for the treatment of heart failure.  N Engl J Med. 2002;  347 1403-1411
• 55 Rathore S S, Curtis J P, Wang Y, Bristow M R, Krumholz H M. Association of serum digoxin concentration and outcomes in patients with heart failure.  JAMA. 2003;  289 871-878
• 56 Luzier A B, Killian A, Wilton J H, Wilson M F, Forrest A, Kazierad D J. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.  Clin Pharmacol Ther. 1999;  66 594-601
• 57 TheMERIT-HFStudyGroup . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).  Lancet. 1999;  353 2001-2007
• 58 Packer M, Bristow M R, Cohn J N, Colucci W S, Fowler M B, Gilbert E M, Shusterman N H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group.  N Engl J Med. 1996;  334 1349-1355
• 59 Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II).  Circulation. 2001;  103 375-380
• 60 CIBISII1999 . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.  Lancet. 1999;  353 9-13
• 61 Wing L M, Reid C M, Ryan P. et al . A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly.  N Engl J Med. 2003;  348 583-592
• 62 Mackay F J, Pearce G L, Mann R D. Cough and angiotensin II receptor antagonists: cause or confounding?.  Br J Clin Pharmacol. 1999;  47 111-114
• 63 Ridker P M, Cook N R, Lee I M. et al . A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.  N Engl J Med. 2005;  352 1293-1304
• 64 Martin R M, Biswas P N, Freemantle S N, Pearce G L, Mann R D. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies.  Br J Clin Pharmacol. 1998;  46 505-511
• 65 Solomon C G, Hu F B, Dunaif A. et al . Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 2013-2017